Ocular Therapeutix (NASDAQ:OCUL) Hits New 1-Year Low – Here’s Why

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) shares hit a new 52-week low during mid-day trading on Thursday. The stock traded as low as $5.78 and last traded at $5.8340, with a volume of 614,997 shares changing hands. The stock had previously closed at $5.94.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Wall Street Zen lowered Ocular Therapeutix from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 14th. Needham & Company LLC reissued a “buy” rating and issued a $18.00 target price on shares of Ocular Therapeutix in a research report on Monday, October 19th. UBS Group started coverage on shares of Ocular Therapeutix in a report on Sunday, October 11th. They issued a “buy” rating and a $14.00 target price for the company. Chardan Capital reaffirmed a “buy” rating and set a $23.00 price target on shares of Ocular Therapeutix in a research report on Friday, October 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $28.00 price target on shares of Ocular Therapeutix in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $23.83.

Get Our Latest Report on OCUL

Ocular Therapeutix Stock Down 4.9%

The company has a quick ratio of 9.05, a current ratio of 9.12 and a debt-to-equity ratio of 0.17. The firm’s 50 day moving average price is $7.49 and its two-hundred day moving average price is $8.82.

Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.06). Ocular Therapeutix had a negative net margin of 648.64% and a negative return on equity of 59.95%. The business had revenue of $12.87 million during the quarter, compared to analysts’ expectations of $14.27 million. During the same period in the prior year, the company posted ($0.38) EPS. The company’s revenue for the quarter was down 11.5% on a year-over-year basis. On average, research analysts predict that Ocular Therapeutix, Inc. will post -1.61 EPS for the current year.

Insider Activity at Ocular Therapeutix

In related news, insider Peter Kaiser sold 9,990 shares of Ocular Therapeutix stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $7.05, for a total value of $70,429.50. Following the completion of the sale, the insider owned 254,388 shares in the company, valued at approximately $1,793,435.40. The trade was a 3.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jeffrey Heier sold 10,869 shares of the stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $7.05, for a total transaction of $76,626.45. Following the transaction, the insider directly owned 307,457 shares in the company, valued at $2,167,571.85. The trade was a 3.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 98,090 shares of company stock worth $787,920. 3.10% of the stock is currently owned by insiders.

Institutional Trading of Ocular Therapeutix

Large investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Ocular Therapeutix during the second quarter worth approximately $190,278,000. Marshall Wace LLP grew its holdings in shares of Ocular Therapeutix by 2,047.2% during the 3rd quarter. Marshall Wace LLP now owns 2,706,184 shares of the biopharmaceutical company’s stock valued at $20,756,000 after acquiring an additional 2,580,151 shares in the last quarter. Commodore Capital LP acquired a new position in shares of Ocular Therapeutix in the first quarter worth $21,810,000. Liontrust Investment Partners LLP acquired a new position in shares of Ocular Therapeutix in the third quarter worth $16,596,000. Finally, Readystate Asset Management LP purchased a new stake in shares of Ocular Therapeutix during the first quarter worth $7,484,000. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix Company Profile

(Get Free Report)

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.

Further Reading

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.